Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a commercial-stage diagnostics company that describes itself as a leading provider of autoimmune diagnostics and autoimmune testing solutions. Based in San Diego County, California, Exagen focuses on chronic and debilitating autoimmune conditions, particularly autoimmune rheumatic diseases. Its news flow reflects both its operational performance and its scientific and clinical activities in this specialized area.
Company news frequently covers financial results and operational updates, including quarterly earnings releases, preliminary annual results, and related guidance. These updates often discuss revenue trends, test volume for the AVISE CTD panel, average selling price metrics, and cash and cash equivalents, giving investors insight into Exagen’s commercial progress as an autoimmune diagnostics provider.
Exagen’s news also highlights developments in its testing portfolio and research programs. The company reports on enhancements to AVISE CTD, such as the commercial launch of seronegative rheumatoid arthritis markers for anti-PAD4, and on scientific milestones like the acceptance of multiple abstracts at the American College of Rheumatology’s annual meeting. These abstracts address topics including urinary biomarker panels for lupus nephritis, kidney-specific biomarker panels, T cell biomarkers, and multianalyte lupus risk scores.
Additional announcements include participation in healthcare and diagnostics investor conferences and leadership appointments, such as the addition of a Chief Scientific Officer and new board members with experience in life sciences and medical technology. Together, these news items give a view into Exagen’s financial performance, scientific focus, and corporate development. Investors and observers can use the XGN news page to follow how the company reports on its autoimmune testing business, research activities, and strategic initiatives over time.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen (Nasdaq: XGN) will participate in the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021. CEO Ron Rocca and CFO Kamal Adawi will host a virtual fireside chat on August 12 at 12:00 PM EST. The session can be accessed through Exagen’s website.
Exagen aims to advance care for autoimmune disease patients with innovative testing solutions, including products under its AVISE® brand. For more details, visit their website.
Exagen Inc. (Nasdaq: XGN) will announce its financial results for Q2 2021 on August 9, 2021, post-market close. Key executives, including CEO Ron Rocca and CFO Kamal Adawi, will lead a conference call at 4:30 PM Eastern Time to review the results. Interested parties can join the call by phone or through a webcast available on Exagen’s investor relations website. A replay of the call will be accessible until August 16, 2021. Exagen focuses on autoimmune testing solutions, aiming to enhance patient care through its AVISE® brand products.
Exagen Inc. (Nasdaq: XGN) announced the publication of a clinical utility study in Lupus & Science Medicine demonstrating the effectiveness of the AVISE Lupus test. Conducted with 12 rheumatology practices, the study revealed that the AVISE test enhances physician confidence in diagnosing systemic lupus erythematosus (SLE) and informs treatment decisions. The results showed increased certainty in SLE diagnoses with higher AVISE scores. Exagen aims to support rheumatologists in managing autoimmune diseases through innovative testing solutions.
Exagen Inc. (Nasdaq: XGN) announced that stockholders have elected Mr. Frank Stokes as an independent member of its Board of Directors during the Annual Meeting on June 17, 2021. Mr. Stokes will also chair the Audit Committee. His experience as a CFO and investment banker, particularly in the life sciences sector, is expected to contribute significantly to Exagen's growth strategy. He aims to enhance Exagen's commitment to improving patient care through innovative autoimmune testing solutions.
Exagen Inc. (Nasdaq: XGN) announced its participation in the William Blair 41st Annual Growth Stock Conference from June 1-3, 2021. The company will host a virtual fireside chat on June 2 at 11:20 AM EDT, featuring President and CEO Ron Rocca and CFO Kamal Adawi. Interested individuals can access the live webcast through Exagen’s website. Exagen focuses on autoimmune testing solutions, aiming to improve care for chronic autoimmune disease patients with innovative AVISE® testing products.
Exagen Inc. (XGN) reported a record revenue of $10.6 million for Q1 2021, up from $9.6 million in Q1 2020, driven by a significant increase in testing volumes. The company delivered 29,029 AVISE® CTD tests and achieved a record of 1,763 ordering healthcare providers. Operating expenses rose to $16.2 million, resulting in a net loss of $6.2 million, compared to a net loss of $5.6 million in the prior year. Exagen maintains its 2021 revenue guidance of $47 million to $49 million.
Exagen Inc. (Nasdaq: XGN) has entered a research collaboration and exclusive license agreement with Allegheny Health Network (AHN) to develop novel patented biomarkers for autoimmune diseases such as systemic lupus erythematosus (SLE). Exagen will gain exclusive rights to four distinct families of inventions and access to AHN's clinical biobank. The collaboration aims to enhance the existing AVISE® testing portfolio using advanced technology known as Cell-Bound Complement Activation Products (CB-CAPs), which were previously developed in conjunction with AHN researchers.
Exagen Inc. (Nasdaq: XGN) has announced its new campaign, 'Know With AVISE,' coinciding with Lupus Awareness Month. This initiative aims to educate the public on the importance of timely diagnosis and monitoring for Systemic Lupus Erythematosus (SLE). In collaboration with the Lupus Foundation of America and LupusChick, Exagen will focus on various stages of the lupus patient journey throughout May. The campaign highlights diagnostic challenges and health disparities while encouraging disease management. Exagen is committed to enhancing care for autoimmune disease patients through innovative testing solutions.
Exagen Inc. (Nasdaq: XGN) will release its financial results for Q1 2021 on May 11, 2021, after market close. A conference call hosted by executives including CEO Ron Rocca and CFO Kamal Adawi will take place at 4:30 PM ET to discuss the results. Interested parties can access the call through dial-in numbers or via the company's investor relations website. A replay will be available through May 18, 2021. Exagen focuses on autoimmune testing solutions and aims to enhance diagnosis and treatment for diseases like rheumatoid arthritis and lupus.
Exagen Inc. (Nasdaq: XGN) has announced a collaboration with Emory University to study the long-term effects of COVID-19 on autoimmune diseases. The longitudinal study will focus on biomarkers related to lupus and rheumatoid arthritis in mild/moderate COVID-19 patients, particularly those treated with dexamethasone. Dr. Ignacio Sanz from Emory emphasized the need for insights into the autoimmune response post-infection. Exagen's President and CEO, Ron Rocca, expressed excitement about leveraging their AVISE® testing portfolio to enhance patient care in this area.